Demographic and baseline characteristics (n=50)
| Variable | Value |
| Age, years, mean (SD) (range) | 63.9 (14.5) (30–88) |
| Male sex, n (%) | 48 (96%) |
| Disease duration, months, median (IQR) (range) | 78 (24; 132) (1–468) |
| No of gout attacks within 12 weeks, median (IQR) (range) | 2 (1; 4) (0–6) |
| No of gout attacks within 4 weeks, median (IQR) (range) | 1 (1; 1) (0–4) |
| VAS pain, median (IQR) (range) | 35 (15; 55) (0–95) |
| HAQ, median (IQR) (range) | 0 (0; 0.375) (0–1.375) |
| No of tender joints (0–60), median (IQR) (range) | 2 (1; 4) (0–18) |
| No of swollen joints (0–60), median (IQR) (range) | 1 (0; 2) (0–14) |
| P-urate (mmol/L), mean (SD) (range) | 0.49 (0.10) (0.32–0.78) |
| No of patients on urate-lowering therapy at inclusion (%) | 9/50 (18%) |
| Self-reported gout attacks (ever) (%) | |
| Forefoot | 43 (86%) |
| Midfoot | 9 (18%) |
| Ankle | 27 (54%) |
| Knee | 12 (24%) |
| Finger and/or wrist | 16 (32%) |
| Elbow | 1 (2%) |
| Body mass index, kg/m2, mean (SD) (range) | 28.7 (5.5) (18.9–41.9) |
| Units of alcohol per day, median (IQR) (range) | 0.5 (0; 2) (0–8) |
| No of smokers (%) | 25 (50%) |
| HbA1c (mmol/mol), mean (SD) (range) | 41.3 (8.5) (29–68) |
| Cholesterol (mmol/L), mean (SD) (range) | 4.9 (1.3) (2.7–8.4) |
| CRP (mg/L), median (IQR) (range) | 7.0 (0.9; 24) (0.3–120) |
| eGFR (mL/min), median (IQR) (range) | 72.5 (57; 90) (21–90) |
| No of patients with comorbidities (%) | 39 (78%) |
| Most common comorbidities (n (%)) | |
| Cardiovascular diseases | 17 (34%) |
| Diabetes | 13 (26%) |
| Hypertension | 15 (30%) |
| Kidney disease | 18 (36%) |
CRP, C reactive protein; eGFR, estimated glomerular filtration rate ; HAQ, Health Assessment Questionnaire; VAS, visual analogue scale.